Company Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 19/06/2024 am IST 5-day change 1st Jan Change
130.9 USD -3.27% Intraday chart for Neurocrine Biosciences, Inc. -2.79% -0.68%

Business Summary

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Number of employees: 1,448

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceuticals
100.0 %
1,489 100.0 % 1,887 100.0 % +26.76%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1,489 100.0 % 1,887 100.0 % +26.76%

Managers

Managers TitleAgeSince
Founder 66 01/92/01
Director of Finance/CFO 44 01/17/01
Chief Tech/Sci/R&D Officer 60 30/21/30
Chief Tech/Sci/R&D Officer 60 08/18/08
Chief Operating Officer - 01/96/01
Chief Tech/Sci/R&D Officer 65 01/93/01
Director/Board Member 73 01/93/01
Investor Relations Contact - -
General Counsel 58 01/21/01
Corporate Officer/Principal 44 30/19/30

Members of the board

Members of the board TitleAgeSince
Director/Board Member 75 01/99/01
Director/Board Member 72 01/15/01
Founder 66 01/92/01
Director/Board Member 71 11/23/11
Chairman 75 08/10/08
Director/Board Member 62 01/98/01
Director/Board Member 73 01/93/01
Director/Board Member 58 01/98/01
Director/Board Member 49 03/20/03
Director/Board Member 54 15/21/15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 100,637,227 98,821,809 ( 98.20 %) 0 98.20 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
11.90 %
11,976,572 11.90 % 1 622 M $
Vanguard Fiduciary Trust Co.
9.868 %
9,930,926 9.868 % 1 345 M $
3,989,961 3.965 % 540 M $
JPMorgan Investment Management, Inc.
2.275 %
2,289,716 2.275 % 310 M $
Renaissance Technologies LLC
2.237 %
2,251,646 2.237 % 305 M $
Eaton Vance Management
2.047 %
2,060,017 2.047 % 279 M $
Bellevue Asset Management AG
2.043 %
2,055,874 2.043 % 278 M $
T. Rowe Price International Ltd.
1.809 %
1,820,796 1.809 % 247 M $
Geode Capital Management LLC
1.703 %
1,713,714 1.703 % 232 M $
BlackRock Life Ltd.
1.466 %
1,475,701 1.466 % 200 M $

Holdings

NameEquities%Valuation
8,575,316 15.77% 72,032,654 $

Company contact information

Neurocrine Biosciences, Inc.

6027 Edgewood Bend Court

92130, San Diego

+858 617 7600

http://www.neurocrine.com
address Neurocrine Biosciences, Inc.(NBIX)
  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. Company Neurocrine Biosciences, Inc.